Campbell & CO Investment Adviser LLC Veracyte, Inc. Transaction History

Campbell & CO Investment Adviser LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$18.86 - $23.55 $1.05 Million - $1.3 Million	-55,413 Reduced 74.01%	19,462 $421,000
Q1 2024 May 10, 2024	SELL	$21.0 - $29.1 $500,241 - $693,191	-23,821 Reduced 24.14%	74,875 $1.66 Million
Q4 2023 Feb 13, 2024	BUY	$19.72 - $28.68 $1.95 Million - $2.83 Million	98,696 New	98,696 $2.72 Million
Q4 2022 Feb 14, 2023	SELL	$15.31 - $29.94 $16,779 - $32,814	-1,096 Reduced 3.65%	28,895 $685,000
Q3 2022 Nov 14, 2022	BUY	$16.58 - $27.9 $497,250 - $836,748	29,991 New	29,991 $498,000
Q3 2021 Nov 10, 2021	SELL	$35.62 - $52.97 $211,938 - $315,171	-5,950 Closed	0 $0
Q2 2021 Aug 11, 2021	BUY	$32.94 - $56.62 $195,993 - $336,889	5,950 New	5,950 $238,000

320

80.6M

134K

13.3K

Ticker VCYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,575,904
Market Cap $2.97B
Description
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...

Get notified when there are updates to the investment portfolio of Campbell & CO Investment Adviser LLC, based on Form 13F filings with the SEC.

Stay updated on Campbell & CO Investment Adviser LLC with notifications on news.